Focal segmental glomerulosclerosis epidemiology and demographics: Difference between revisions
Olufunmilola (talk | contribs) No edit summary |
Olufunmilola (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Focal segmental glomerulosclerosis}} | {{Focal segmental glomerulosclerosis}} | ||
{{ | {{CMG}}; '''Associate Editor-In-Chief:’’’ {{OO}} | ||
==Epidemiology & Demographics== | ==Epidemiology & Demographics== | ||
Focal segmental glomerulosclerosis (FSGS) is considered the most common cause of nephrotic syndrome worldwide and the most common primary renal cause of end-stage renal disease (ESRD) in whites and blacks, contributing to approximately 2% of ESRD.<ref name="pmid15492947">{{cite journal| author=Kitiyakara C, Eggers P, Kopp JB| title=Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. | journal=Am J Kidney Dis | year= 2004 | volume= 44 | issue= 5 | pages= 815-25 | pmid=15492947 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15492947 }} </ref> biopsy-proven study done by Sim JJ, Batech M, et al)in 2011, shows that FSGS remains the most common primary glomerulonephropathy across ethnic and racial distribution in the United State <ref name="pmid27138468">{{cite journal| author=Sim JJ, Batech M, Hever A, Harrison TN, Avelar T, Kanter MH et al.| title=Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population. | journal=Am J Kidney Dis | year= 2016 | volume= 68 | issue= 4 | pages= 533-44 | pmid=27138468 | doi=10.1053/j.ajkd.2016.03.416 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27138468 }} </ref>. | Focal segmental glomerulosclerosis (FSGS) is considered the most common cause of nephrotic syndrome worldwide and the most common primary renal cause of end-stage renal disease (ESRD) in whites and blacks, contributing to approximately 2% of ESRD.<ref name="pmid15492947">{{cite journal| author=Kitiyakara C, Eggers P, Kopp JB| title=Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. | journal=Am J Kidney Dis | year= 2004 | volume= 44 | issue= 5 | pages= 815-25 | pmid=15492947 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15492947 }} </ref> biopsy-proven study done by Sim JJ, Batech M, et al)in 2011, shows that FSGS remains the most common primary glomerulonephropathy across ethnic and racial distribution in the United State <ref name="pmid27138468">{{cite journal| author=Sim JJ, Batech M, Hever A, Harrison TN, Avelar T, Kanter MH et al.| title=Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population. | journal=Am J Kidney Dis | year= 2016 | volume= 68 | issue= 4 | pages= 533-44 | pmid=27138468 | doi=10.1053/j.ajkd.2016.03.416 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27138468 }} </ref>. | ||
Revision as of 16:40, 18 October 2016
|
Focal segmental glomerulosclerosis Microchapters |
|
Differentiating Focal segmental glomerulosclerosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Focal segmental glomerulosclerosis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Focal segmental glomerulosclerosis epidemiology and demographics |
|
FDA on Focal segmental glomerulosclerosis epidemiology and demographics |
|
CDC on Focal segmental glomerulosclerosis epidemiology and demographics |
|
Focal segmental glomerulosclerosis epidemiology and demographics in the news |
|
Blogs on Focal segmental glomerulosclerosis epidemiology and demographics |
|
Directions to Hospitals Treating Focal segmental glomerulosclerosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief:’’’ Olufunmilola Olubukola M.D.[2]
Epidemiology & Demographics
Focal segmental glomerulosclerosis (FSGS) is considered the most common cause of nephrotic syndrome worldwide and the most common primary renal cause of end-stage renal disease (ESRD) in whites and blacks, contributing to approximately 2% of ESRD.[1] biopsy-proven study done by Sim JJ, Batech M, et al)in 2011, shows that FSGS remains the most common primary glomerulonephropathy across ethnic and racial distribution in the United State [2].
FSGS is more common in blacks. It accounts for approximately 35% of nephrotic syndromes in all cases and approximately 50% of nephrotic syndrome in blacks.[3] The disease is considered a disease of the adult population (vs. minimal change disease which is much more common among children). In a 21-year follow-up study that excludes HIV-associated nephropathy, the median age of FSGS ESRD is 40-49 years in black adults and 70-79 in white and Asian adults.[1] The male to female ratio is 1.5-2 to 1.[1]
Data from the United States Renal Data System (USRDS) collected over 21 years shows that FSGS is the most common renal pathology identified in end-stage renal disease (ESRD) patients in the United States.[1] The prevalence of FSGS as a lesion associated with ESRD has risen. In 1980, FSGS was the cause of ESRD in only 0.2 percent of patients; by 2000, it was responsible for 2.3 percent of cases.
References
- ↑ 1.0 1.1 1.2 1.3 Kitiyakara C, Eggers P, Kopp JB (2004). "Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States". Am J Kidney Dis. 44 (5): 815–25. PMID 15492947.
- ↑ Sim JJ, Batech M, Hever A, Harrison TN, Avelar T, Kanter MH; et al. (2016). "Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population". Am J Kidney Dis. 68 (4): 533–44. doi:10.1053/j.ajkd.2016.03.416. PMID 27138468.
- ↑ Hogg R, Middleton J, Vehaskari VM (2007). "Focal segmental glomerulosclerosis--epidemiology aspects in children and adults". Pediatr Nephrol. 22 (2): 183–6. doi:10.1007/s00467-006-0370-5. PMC 1764601. PMID 17151873.